Clinical Trials

Inclusion Criteria:    

1. Subjects with a histological confirmed diagnosis of testicular cancer who are destined to initiate standard of care therapeutic interventions. This includes testicular cancer subjects with evidence of clinically or biochemically progressive disease post surgical or radiation treatments for localized stage disease as deemed by the treating physician. Biochemical evidence of progressive disease is defined as a serially rising serum tumor marker (AFP-Alpha Feto-Protein; B-HCG-beta human chorionic gonadotropin or LDH). 
2. Subjects with non-localized kidney cancer being followed or treated at Mayo Clinic as part of standard clinical care.
3. Age: 18 to 100 years
4. Subject must be able to sign an informed consent. Informed consent must be signed at the time of enrollment and/or collection of any specimen and/or clinical data (other than PHI needed to screen and identify patients, which will be promptly discarded in a secure fashion if patient is not enrolled on study).

Exclusion Criteria:   

1. Subjects either incarcerated or with limited decision making capacity.
2. Subjects clinically judged to be at increased risk of bleeding from phlebotomy.
3. Subjects with hemoglobin
4. Subjects with a previous history of known second non-GU malignancy in the past five years.